Clinical Benefits of Denosumab vs Zoledronate in Postmenopausal Women Previously Treated with Alendronate: A Two-Year Retrospective Study
In postmenopausal osteoporosis patients transitioning from oral ALN to other antiresorptive therapies, Dmab is demonstrated superior efficacy over ZOL in lowering risk of new-onset vertebral and overall fractures and sustaining BMD improvements over 24 months. These findings suggest that Dmab may represent a preferential strategy for optimizing clinical outcomes in sequential anti-osteoporosis treatment protocols.
Authors
- Chun Wang (ORCID: https://orcid.org/0000-0003-4124-1575)
- Zhenlin Zhang (ORCID: https://orcid.org/0000-0002-4339-1617)
- Yazhao Mei
- Na Ren
- Li Shen (ORCID: https://orcid.org/0000-0003-4838-0770)
- Ya Wang (ORCID: https://orcid.org/0000-0001-6229-4495)
- Ziyuan Wang (ORCID: https://orcid.org/0000-0002-7095-8527)
- Jie‐Mei Gu
Institutions
- Shanghai Jiao Tong University (CN)
- Shanghai Sixth People's Hospital (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-11-01
- DOI
- https://doi.org/10.2147/dddt.s533224
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Shanghai Jiao Tong University
- School of Medicine, Shanghai Jiao Tong University
- Northwest Fisheries Science Center